Unprecedented Biotech Bankruptcies Erupt Amid Finance Crisis
Date: 24.11.2008
The global economic crisis has cut funding for biotechnology companies to the lowest level in a decade, triggering bankruptcies and threatening development of drugs based on biomedical breakthroughs.
In the past month, at least five biotechnology businesses have sought bankruptcy protection, according to company news releases, and others may be heading toward a similar fate. Those at highest risk have experimental compounds moving into costly human research. Peptimmune Inc., a 6-year-old closely held firm, says it’s struggling to pay for clinical trials of its promising multiple sclerosis drug.
More on "bloomberg.com":[ http://www.bloomberg.com/apps/news?pid=20601109&sid=a55.vWF5YPhA]
